1. Home
  2. RBC vs EXEL Comparison

RBC vs EXEL Comparison

Compare RBC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBC
  • EXEL
  • Stock Information
  • Founded
  • RBC 1919
  • EXEL 1994
  • Country
  • RBC United States
  • EXEL United States
  • Employees
  • RBC N/A
  • EXEL 1147
  • Industry
  • RBC Metal Fabrications
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RBC Industrials
  • EXEL Health Care
  • Exchange
  • RBC Nasdaq
  • EXEL Nasdaq
  • Market Cap
  • RBC 12.8B
  • EXEL 10.4B
  • IPO Year
  • RBC 2005
  • EXEL 2000
  • Fundamental
  • Price
  • RBC $394.69
  • EXEL $38.31
  • Analyst Decision
  • RBC Buy
  • EXEL Buy
  • Analyst Count
  • RBC 6
  • EXEL 21
  • Target Price
  • RBC $411.00
  • EXEL $43.65
  • AVG Volume (30 Days)
  • RBC 161.4K
  • EXEL 4.0M
  • Earning Date
  • RBC 08-01-2025
  • EXEL 07-28-2025
  • Dividend Yield
  • RBC N/A
  • EXEL N/A
  • EPS Growth
  • RBC 17.43
  • EXEL 81.76
  • EPS
  • RBC 7.97
  • EXEL 2.08
  • Revenue
  • RBC $1,666,000,000.00
  • EXEL $2,230,005,000.00
  • Revenue This Year
  • RBC $10.07
  • EXEL $9.88
  • Revenue Next Year
  • RBC $8.44
  • EXEL $12.59
  • P/E Ratio
  • RBC $49.51
  • EXEL $18.45
  • Revenue Growth
  • RBC 5.48
  • EXEL 10.73
  • 52 Week Low
  • RBC $272.50
  • EXEL $25.12
  • 52 Week High
  • RBC $416.33
  • EXEL $49.62
  • Technical
  • Relative Strength Index (RSI)
  • RBC 50.56
  • EXEL 41.08
  • Support Level
  • RBC $389.97
  • EXEL $37.01
  • Resistance Level
  • RBC $411.12
  • EXEL $38.78
  • Average True Range (ATR)
  • RBC 10.51
  • EXEL 1.12
  • MACD
  • RBC -0.35
  • EXEL 0.07
  • Stochastic Oscillator
  • RBC 48.09
  • EXEL 83.79

About RBC RBC Bearings Incorporated

RBC Bearings Inc is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: Industrial, which derives maximum revenue, and Aerospace/Defense. The Aerospace/Defense segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the Industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: